Kodiak Sciences (NASDAQ:KOD) Sees Strong Trading Volume Following Analyst Upgrade

Kodiak Sciences Inc. (NASDAQ:KOD) saw unusually-high trading volume on Tuesday after Lifesci Capital raised their price target on the stock from $85.00 to $145.00. Lifesci Capital currently has an outperform rating on the stock. Approximately 1,414,667 shares were traded during mid-day trading, an increase of 36% from the previous session’s volume of 1,043,171 shares. The stock last traded at $88.0720 and had previously closed at $89.92.

Other analysts have also recently issued reports about the stock. The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research note on Thursday, September 24th. They set a “neutral” rating and a $36.00 price objective for the company. Wall Street Zen lowered Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a research note on Friday, July 10th. UBS Group boosted their price target on Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a report on Monday. Finally, HC Wainwright raised their price objective on shares of Kodiak Sciences from $58.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kodiak Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $90.86.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Major Phase 3 clinical success: Zenkuda and tabirafusp-ted (formerly KSI-501) both met their primary endpoints in the DAYBREAK trial. The treatments reportedly delivered vision outcomes comparable to Eylea, while Kodiak highlighted their potential for longer-lasting disease control. Why Kodiak Sciences Skyrocketed Today
• Positive Sentiment: Regulatory path is advancing: Kodiak plans to seek regulatory approval for Zenkuda following the successful trial, bringing a potentially commercial retinal medicine closer to market. The global retinal-drug market is expected to exceed $32 billion by the end of the decade. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Positive Sentiment: Analyst sentiment strengthened: UBS raised its price target from $80 to $120 and assigned a “buy” rating. Lifesci Capital raised its target from $85 to $145 and rated the shares “outperform,” while HC Wainwright increased its target from $58 to $96 and maintained a “buy” rating.
• Neutral Sentiment: Investor attention and volatility are elevated: KOD reached a new 12-month high and has risen substantially over the past year, reflecting a sharp reassessment of its prospects. The move also leaves the stock vulnerable to profit-taking and large price swings. Kodiak Sciences Shares Hit 52-Week High After Positive Phase 3 Trial
• Negative Sentiment: Bearish hedging appeared in the options market: Traders purchased 21,273 put options, roughly 1,361% above typical daily volume. This may signal hedging or speculation that the stock’s rally could reverse.
• Negative Sentiment: Execution and valuation risks remain: Kodiak still must complete regulatory filings, obtain approval and successfully commercialize the products. The company remains loss-making, and the stock’s elevated valuation and dependence on a small number of late-stage assets increase downside risk if follow-up data or regulators disappoint.

Institutional Investors Weigh In On Kodiak Sciences

A number of hedge funds have recently modified their holdings of the company. Engineers Gate Manager LP grew its holdings in shares of Kodiak Sciences by 145.8% during the 2nd quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock worth $1,151,000 after purchasing an additional 17,520 shares during the period. Squarepoint Ops LLC increased its position in shares of Kodiak Sciences by 112.6% during the 2nd quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock worth $5,887,000 after purchasing an additional 80,042 shares during the last quarter. Arizona State Retirement System raised its holdings in Kodiak Sciences by 6.9% in the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock valued at $332,000 after buying an additional 554 shares during the period. Hsbc Holdings PLC purchased a new stake in Kodiak Sciences in the 2nd quarter valued at about $232,000. Finally, Wellington Management Group LLP lifted its position in Kodiak Sciences by 81.9% in the second quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock valued at $30,919,000 after buying an additional 357,284 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Price Performance

The company has a market cap of $5.43 billion, a PE ratio of -20.63 and a beta of 2.18. The company’s 50 day simple moving average is $39.29 and its two-hundred day simple moving average is $37.80.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). Sell-side analysts expect that Kodiak Sciences Inc. will post -3.89 EPS for the current fiscal year.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.